SecBot SecBot
8-K ·Filed May 14, 2026

PYXS

Pyxis Oncology, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed6mo ago SEC0001193125-26-222818
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The stock will trade on pipeline catalysts, not quarterly financials. Key binary event is the mid-2026 monotherapy data update for MICVO in 2L+ HNSCC, which will determine whether the dose-cap strategy preserves efficacy while improving safety. Cash runway into Q4 2026 provides ~2 quarters of operating visibility post-data, a positive readout could trigger financing, while a negative one would raise survival risk. Monitor for any early look at the data via abstract releases or investor events.

DirectionNeutral
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

Pyxis Oncology reported Q1 2026 financial results, with a net loss of $23.3M ($0.37/share) vs $21.2M ($0.35/share) in Q1 2025, reflecting increased R&D spending on its lead ADC candidate MICVO. The company completed target enrollment in the Phase 1 monotherapy expansion study and remains on track for key mid-2026 and 2H26 data readouts. Cash runway extends into Q4 2026, but the cash burn rate accelerated, with cash and investments declining from $68.3M (Dec 2025) to $42.5M (Mar 2026).

Key Financial Metrics

EPS
−$0.37
est −$0.35 · -5.7%
Rating
in line

Key Facts

  • Net loss of $23.3M ($0.37/share) for Q1 2026 vs $21.2M ($0.35/share) in Q1 2025
  • Cash, cash equivalents, restricted cash, and short-term investments of $42.5M as of March 31, 2026, down from $68.3M at Dec 31, 2025
  • R&D expenses increased to $20.0M from $17.0M YoY, driven by clinical trial costs for MICVO
  • Completed target enrollment in Phase 1 monotherapy dose expansion study of MICVO in 2L+ R/M HNSCC in Q1 2026
  • Updated monotherapy data on track for mid-2026; updated combination data with pembrolizumab on track for 2H26
  • Appointed Nelson Azoulay as Chief Business Officer in May 2026
  • Cash runway expected into Q4 2026

Financial Impact

Net loss widened by $2.1M YoY; cash burn of ~$25.8M in Q1 2026

net losscash positionR&D expenses

Risk Factors

  • Cash runway only into Q4 2026, financing risk if data disappoints or enrollment slows
  • Phase 1 monotherapy data in mid-2026 is binary: dose-cap strategy may reduce efficacy vs the 46% ORR seen in the preliminary December 2025 dataset
  • Single-asset clinical-stage biotech, any safety or efficacy signal failure would be value-destructive
  • No revenue from product sales, fully dependent on non-dilutive funding and capital markets

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
87% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-222818
Document: pyxs-20260514.htm0001193125-26-222818
Document: 0001193125-26-222818-index-headers.html0001193125-26-222818
Document: 0001193125-26-222818-index.html0001193125-26-222818
Document: 0001193125-26-222818.txt0001193125-26-222818
8-K Data (Synthetic)0001193125-26-222818

Track record

25 reports on PYXS

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.94% at T+60 after the Apr 17, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.43 Now $1.41 −1.32% settles Dec 16
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.43 Now $1.41 −1.40% settles Dec 16
  3. Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.55 Now $1.41 −9.14% settles Dec 15
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $1.61 Now $1.41 −12.42% settles Dec 4
  5. Nov 3, 202613d ago SC 13G/A Bearish 5/10 Entry $1.64 Now $1.41 +14.02% settles Dec 2
  6. Oct 27, 202620d ago Press Release Neutral 4/10 Entry $1.84 Now $1.41 −23.37% settles Nov 24
  7. Oct 21, 202626d ago DEF 14A Bearish 6/10 Entry $1.71 Now $1.41 +17.54% settles Nov 19
  8. Oct 9, 20265w ago SC 13G/A Neutral 4/10 Entry $2.03 to $1.66 Now $1.41 −30.54% ▼ −18.23% −12.67% vs SPY
  9. Oct 2, 20266w ago SC 13G/A Neutral 4/10 Entry $2.14 to $1.81 Now $1.41 −34.11% ▼ −15.42% −13.61% vs SPY
  10. Oct 2, 20266w ago Press Release Bearish 7/10 Entry $2.14 to $1.81 Now $1.41 +34.11% ▲ +15.42% +13.61% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026